Even though over-expression of both CPT1A and ATP1B1 enhances the paclitaxel resistance of ovarian cancer cells, a higher CPT1A expression level allows cancer cells the obtention of stronger metastasis ability, while a high ATP1B1 expression level inhibits metastasis. Here, CPT1A is linked to ovarian carcinoma.